Literature DB >> 20445000

Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma.

Erwin G Van Meir1, Costas G Hadjipanayis, Andrew D Norden, Hui-Kuo Shu, Patrick Y Wen, Jeffrey J Olson.   

Abstract

Malignant gliomas are the most common and deadly brain tumors. Nevertheless, survival for patients with glioblastoma, the most aggressive glioma, although individually variable, has improved from an average of 10 months to 14 months after diagnosis in the last 5 years due to improvements in the standard of care. Radiotherapy has been of key importance to the treatment of these lesions for decades, and the ability to focus the beam and tailor it to the irregular contours of brain tumors and minimize the dose to nearby critical structures with intensity-modulated or image-guided techniques has improved greatly. Temozolomide, an alkylating agent with simple oral administration and a favorable toxicity profile, is used in conjunction with and after radiotherapy. Newer surgical techniques, such as fluorescence-guided resection and neuroendoscopic approaches, have become important in the management of malignant gliomas. Furthermore, new discoveries are being made in basic and translational research, which are likely to improve this situation further in the next 10 years. These include agents that block 1 or more of the disordered tumor proliferation signaling pathways, and that overcome resistance to already existing treatments. Targeted therapies such as antiangiogenic therapy with antivascular endothelial growth factor antibodies (bevacizumab) are finding their way into clinical practice. Large-scale research efforts are ongoing to provide a comprehensive understanding of all the genetic alterations and gene expression changes underlying glioma formation. These have already refined the classification of glioblastoma into 4 distinct molecular entities that may lead to different treatment regimens. The role of cancer stem-like cells is another area of active investigation. There is definite hope that by 2020, new cocktails of drugs will be available to target the key molecular pathways involved in gliomas and reduce their mortality and morbidity, a positive development for patients, their families, and medical professionals alike.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20445000      PMCID: PMC2888474          DOI: 10.3322/caac.20069

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN: 0007-9235            Impact factor:   508.702


  112 in total

1.  Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin.

Authors:  T A Libermann; H R Nusbaum; N Razon; R Kris; I Lax; H Soreq; N Whittle; M D Waterfield; A Ullrich; J Schlessinger
Journal:  Nature       Date:  1985 Jan 10-18       Impact factor: 49.962

2.  Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy.

Authors:  June L Chan; Susan W Lee; Benedick A Fraass; Daniel P Normolle; Harry S Greenberg; Larry R Junck; Stephen S Gebarski; Howard M Sandler
Journal:  J Clin Oncol       Date:  2002-03-15       Impact factor: 44.544

3.  A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: final report of an RTOG study.

Authors:  D F Nelson; M Diener-West; A S Weinstein; D Schoenfeld; J S Nelson; W T Sause; C H Chang; R Goodman; S Carabell
Journal:  Int J Radiat Oncol Biol Phys       Date:  1986-10       Impact factor: 7.038

Review 4.  Tumor initiating cells in malignant gliomas: biology and implications for therapy.

Authors:  Costas G Hadjipanayis; Erwin G Van Meir
Journal:  J Mol Med (Berl)       Date:  2009-02-03       Impact factor: 4.599

5.  A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation.

Authors:  Brian Thiessen; Clinton Stewart; Ming Tsao; Suzanne Kamel-Reid; Paula Schaiquevich; Warren Mason; Jacob Easaw; Karl Belanger; Peter Forsyth; Lynn McIntosh; Elizabeth Eisenhauer
Journal:  Cancer Chemother Pharmacol       Date:  2010-01       Impact factor: 3.333

6.  Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha.

Authors:  Shimin Zhao; Yan Lin; Wei Xu; Wenqing Jiang; Zhengyu Zha; Pu Wang; Wei Yu; Zhiqiang Li; Lingling Gong; Yingjie Peng; Jianping Ding; Qunying Lei; Kun-Liang Guan; Yue Xiong
Journal:  Science       Date:  2009-04-10       Impact factor: 47.728

7.  Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours.

Authors:  Hans Skovgaard Poulsen; Kirsten Grunnet; Morten Sorensen; Preben Olsen; Benedikte Hasselbalch; Knud Nelausen; Michael Kosteljanetz; Ulrik Lassen
Journal:  Acta Oncol       Date:  2009       Impact factor: 4.089

8.  Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival.

Authors:  Ashwatha Narayana; Patrick Kelly; John Golfinos; Erik Parker; Glyn Johnson; Edmond Knopp; David Zagzag; Ingeborg Fischer; Shahzad Raza; Praveen Medabalmi; Patricia Eagan; Michael L Gruber
Journal:  J Neurosurg       Date:  2009-01       Impact factor: 5.115

Review 9.  Invasion as limitation to anti-angiogenic glioma therapy.

Authors:  K Lamszus; P Kunkel; M Westphal
Journal:  Acta Neurochir Suppl       Date:  2003

10.  Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules.

Authors:  A W Tolcher; S L Gerson; L Denis; C Geyer; L A Hammond; A Patnaik; A D Goetz; G Schwartz; T Edwards; L Reyderman; P Statkevich; D L Cutler; E K Rowinsky
Journal:  Br J Cancer       Date:  2003-04-07       Impact factor: 7.640

View more
  552 in total

1.  Probucol suppresses human glioma cell proliferation in vitro via ROS production and LKB1-AMPK activation.

Authors:  Yong-sheng Jiang; Jing-an Lei; Fang Feng; Qi-ming Liang; Fu-rong Wang
Journal:  Acta Pharmacol Sin       Date:  2014-11-17       Impact factor: 6.150

2.  Brain tumor segmentation based on deep learning and an attention mechanism using MRI multi-modalities brain images.

Authors:  Ramin Ranjbarzadeh; Abbas Bagherian Kasgari; Saeid Jafarzadeh Ghoushchi; Shokofeh Anari; Maryam Naseri; Malika Bendechache
Journal:  Sci Rep       Date:  2021-05-25       Impact factor: 4.379

Review 3.  Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates.

Authors:  Guido Wollmann; Koray Ozduman; Anthony N van den Pol
Journal:  Cancer J       Date:  2012 Jan-Feb       Impact factor: 3.360

4.  Delayed formation of FancD2 foci in glioma stem cells treated with ionizing radiation.

Authors:  Enrico Cappelli; Donatella Vecchio; Guido Frosina
Journal:  J Cancer Res Clin Oncol       Date:  2012-04-07       Impact factor: 4.553

5.  Nanotechnology for energy-based cancer therapies.

Authors:  Kyle Gilstrap; Xiaoxiao Hu; Xiongbin Lu; Xiaoming He
Journal:  Am J Cancer Res       Date:  2011-03-11       Impact factor: 6.166

Review 6.  Metzincin proteases and their inhibitors: foes or friends in nervous system physiology?

Authors:  Santiago Rivera; Michel Khrestchatisky; Leszek Kaczmarek; Gary A Rosenberg; Diane M Jaworski
Journal:  J Neurosci       Date:  2010-11-17       Impact factor: 6.167

7.  MicroRNA-1179 inhibits glioblastoma cell proliferation and cell cycle progression via directly targeting E2F transcription factor 5.

Authors:  Xiupeng Xu; Ning Cai; Tongle Zhi; Zhongyuan Bao; Dong Wang; Yinlong Liu; Kuan Jiang; Liang Fan; Jing Ji; Ning Liu
Journal:  Am J Cancer Res       Date:  2017-08-01       Impact factor: 6.166

Review 8.  Toward 3D biomimetic models to understand the behavior of glioblastoma multiforme cells.

Authors:  Shreyas S Rao; John J Lannutti; Mariano S Viapiano; Atom Sarkar; Jessica O Winter
Journal:  Tissue Eng Part B Rev       Date:  2013-10-30       Impact factor: 6.389

9.  Overexpression of integrin-linked kinase (ILK) promotes glioma cell invasion and migration and down-regulates E-cadherin via the NF-κB pathway.

Authors:  Feng Liang; Shuqin Zhang; Bing Wang; Jianwu Qiu; Yunjie Wang
Journal:  J Mol Histol       Date:  2013-09-13       Impact factor: 2.611

10.  Stage-specific embryonic antigen-4 as a potential therapeutic target in glioblastoma multiforme and other cancers.

Authors:  Yi-Wei Lou; Pao-Yuan Wang; Shih-Chi Yeh; Po-Kai Chuang; Shiou-Ting Li; Chung-Yi Wu; Kay-Hooi Khoo; Michael Hsiao; Tsui-Ling Hsu; Chi-Huey Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-03       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.